Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.

Current Microbiology

Volumn 54, Issue 2, 2007, Pages 85-90

  Gergova, Raina T ^a   Iankov, Ianko D ^a   Haralambieva, Iana H ^a   Mitov, Ivan G ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOOLIGOSACCHARIDE; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; HAEMOPHILUS; IMMUNE RESPONSE; IMMUNIZATION; MORAXELLA CATARRHALIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; COLONY COUNT, MICROBIAL; COMPLEMENT SYSTEM PROTEINS; CROSS REACTIONS; EPITOPES; GUINEA PIGS; HAEMOPHILUS; HUMANS; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MORAXELLA (BRANHAMELLA) CATARRHALIS; SEROTYPING;

HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; MORAXELLA CATARRHALIS; MUS;

EID: 33846321894     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-005-0463-6     Document Type: Article

References (35)

1. Catlin BW (1990) Branhamella catarrhalis: an organism gaining respect as a pathogen. Clin Microbiol Rev 3:293-320
2. Verduin CM, Hol C, Fleer A, et al. (2002) Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev 15:125-144
3. Cunha BA (2001) Pneumonia in the elderly. Clin Microbiol Infect 7:581-588
4. Sethi S, Evans N, Grant BJ, Murphy TF (2002) New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 347:465-471
5. Sethi S, Murphy TF (2001) Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 14:336-363
6. Cripps AW, Kyd J (2003) Bacterial otitis media: current vaccine development strategies. Immunol Cell Biol 81:46-51
7. Chen D, Barniak V, Van Der Meid KR, McMichael JC (1999) The levels and bactericidal capacity of antibodies directed against the UspA1 and UspA2 outer membrane proteins of Moraxella (Branhamella) catarrhalis in adults and children. Infect Immun 67:1310-1316
8. Murphy TF (1996) Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Microbiol Rev 60:267-279
9. Peak IR, Jennings MP, Hood DW, et al. (1996) Tetrameric repeat units associated with virulence factor phase variation in Haemophilus also occur in Neisseria spp. and Moraxella catarrhalis. FEMS Microbiol Lett 137:109-114
10. Gu XX, Chen J, Barenkamp SJ, et al. (1998) Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect Immun 66:1891-1897
11. Holme T, Rahman M, Jansson PE, Widmalm G (1999) The lipopolysaccharide of Moraxella catarrhalis structural relationships and antigenic properties. Eur J Biochem 26:524-529
12. Campagnari AA, Spinola SM, Lesse AJ, et al. (1990) Lipooligosaccharide epitopes shared among gram-negative non-enteric mucosal pathogens. Microb Pathog 8:353-362
13. Fomsgaard JS, Fomsgaard A, Hoiby N, et al. (1991) Comparative immunochemistry of lipopolysaccharides from Branhamella catarrhalis strains. Infect Immun 59:3346-3349
14. Vaneechoutte M, Verschraegen G, Claeys G, et al. (1990) Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens. J Clin Microbiol 28:182-187
15. Hu WG, Chen J, McMichael JC, Gu XX (2001) Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis. Infect Immun 69:1358-1363
16. Oishi K, Tanaka H, Sonoda F, et al. (1996) A monoclonal antibody reactive with a common epitope of Moraxella (Branhamella) catarrhalis lipopolysaccharides. Clin Diagn Lab Immunol 3:351-354
17. Rahman M, Holme T (1996) Antibody response in rabbits to serotype-specific determinants in lipopolysaccharides from Moraxella catarrhalis. J Med Microbiol 44:348-354
18. Burman LA, Leinonen M, Trollfors B (1994) Use of serology to diagnose pneumonia caused by nonencapsulated Haemophilus influenzae and Moraxella catarrhalis. J Infect Dis 170:220-222
19. Jiao X, Hirano T, Hou Y, Gu XX (2002) Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine. Infect Immun 70:5982-5989
20. McMichael JC (2000) Vaccines for Moraxella catarrhalis. Vaccine 19(Suppl1):S101-107
21. Schmitz FJ, Beeck A, Perdikouli M, et al. (2002) Production of BRO beta-lactamases and resistance to complement in European Moraxella catarrhalis isolates. J Clin Microbiol 40:1546-1548
22. Zaleski A, Scheffler NK, Densen P, et al. (2000) Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of Moraxella catarrhalis is a factor in resistance to bactericidal activity mediated by normal human serum. Infect Immun 68:5261-5268
23. Westphal O, Jann K (1965) Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 5:83-91
24. Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497
25. Campbell A (1991) In monoclonal antibody and immunosensor technology. Laboratory techniques in biochemistry and molecular biology, vol. 23 Amsterdam: Elsevier
26. Freudenberg M, Fomsgaard A, Mitov I, Galanos C (1989) ELISA for antibodies to lipid A, lipopolysaccharides and other hydrophobic antigens. Infection 17:322-328
27. Galanos C, Luderitz O, Westphal O (1971) Preparation and properties of antisera against the lipid A component of bacterial lipopolysaccharides. Eur J Biochem 24:116-122
28. Gilsdorf JR, Marrs CF, Foxman B (2004) Haemophilus influenzae: Genetic Variability and Natural Selection To Identify Virulence Factors. Infect Immun 72:(5)2457-2461
29. Mitov I, Freudenberg M, Bamberger U, Galanos C (1993) Cross-binding activity and protective capacity of monoclonal antibodies to Lipid A. Immunobiology 188:1-12
30. Mitov I, Terziiski D (1991) Immunoprophilaxis and immunotherapy of Gram-negative sepsis and shock with antibodies to core glicolipides and lipid of bacterial lipopolysaccharides. Infection 1:383-390
31. Hu WG, Chen J, Battey JF, Gu XX (2000) Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins. Infect Immun 68:4980-4985
32. Rahman M, Jonsson AB, Holme T (1998) Monoclonal antibodies to the epitope alpha-Gal-(1-4)-beta-Gal-(1-4) of Moraxella catarrhalis LPS react with a similar epitope in type IV pili of Neisseria meningitidis. Microb Pathog 24:299-308
33. Murphy TF, Brauer AL, Aebi C, Sethi S (2005) Identification of surface antigens of moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect Immun 73:3471-3478
34. Yu JS, Gu XX (2005) Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect Immun 73:2790-2796
35. Hirano T, Hou Y, Jiao X, Gu XX (2003) Intranasal immunization with a lipooligosaccharide-based conjugate vaccine from non-typeable Haemophilus influenzae enhances bacterial clearance in mouse nasopharynx. FEMS Immunol Med Microbiol 35:1-10